Paul V. Ward

Array ( [id] => 20686562 [patent_doc_number] => 12616690 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-05 [patent_title] => Specific AKT3 activator and uses thereof [patent_app_type] => utility [patent_app_number] => 18/606834 [patent_app_country] => US [patent_app_date] => 2024-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 112 [patent_no_of_words] => 13661 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 232 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18606834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19389373 [patent_doc_number] => 20240279243 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => LIQUID PHARMACEUTICAL COMPOSITION OF GOLD [patent_app_type] => utility [patent_app_number] => 18/606361 [patent_app_country] => US [patent_app_date] => 2024-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23626 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18606361 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19785499 [patent_doc_number] => 20250059178 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-20 [patent_title] => N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/604731 [patent_app_country] => US [patent_app_date] => 2024-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26371 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18604731 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19510488 [patent_doc_number] => 20240342174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => METHODS FOR TREATING OCULAR SURFACE PAIN [patent_app_type] => utility [patent_app_number] => 18/597497 [patent_app_country] => US [patent_app_date] => 2024-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22559 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18597497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19447261 [patent_doc_number] => 20240307391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => METALLOENZYME INHIBITOR COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/443509 [patent_app_country] => US [patent_app_date] => 2024-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 102293 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19777400 [patent_doc_number] => 12226420 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-18 [patent_title] => Theramutein modultors [patent_app_type] => utility [patent_app_number] => 18/433881 [patent_app_country] => US [patent_app_date] => 2024-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 23929 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18433881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19629640 [patent_doc_number] => 20240408089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-12 [patent_title] => DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS [patent_app_type] => utility [patent_app_number] => 18/422704 [patent_app_country] => US [patent_app_date] => 2024-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16439 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18422704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20129135 [patent_doc_number] => 12371437 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Method of preparing camsylate salts of triazolopyrazine derivatives [patent_app_type] => utility [patent_app_number] => 18/395738 [patent_app_country] => US [patent_app_date] => 2023-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 63 [patent_no_of_words] => 5117 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18395738 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19897835 [patent_doc_number] => 12275740 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-15 [patent_title] => Method of inhibiting kinase by camsylate salts of triazolopyrazine derivatives [patent_app_type] => utility [patent_app_number] => 18/395739 [patent_app_country] => US [patent_app_date] => 2023-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 63 [patent_no_of_words] => 5344 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 204 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18395739 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19076478 [patent_doc_number] => 11945828 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-04-02 [patent_title] => Electronically weakly coupled 4,4'-divinylazobenzene-bridged diruthenium complex bearing two Ru(CO)Cl (PiPr3)2 moieties as an inorganic catalyst [patent_app_type] => utility [patent_app_number] => 18/534330 [patent_app_country] => US [patent_app_date] => 2023-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 8 [patent_no_of_words] => 4111 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18534330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19265240 [patent_doc_number] => 20240208939 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN [patent_app_type] => utility [patent_app_number] => 18/532671 [patent_app_country] => US [patent_app_date] => 2023-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25098 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18532671 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19246768 [patent_doc_number] => 20240197752 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY [patent_app_type] => utility [patent_app_number] => 18/519150 [patent_app_country] => US [patent_app_date] => 2023-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46272 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18519150 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19263515 [patent_doc_number] => 20240207212 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION [patent_app_type] => utility [patent_app_number] => 18/517596 [patent_app_country] => US [patent_app_date] => 2023-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30885 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18517596 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19921689 [patent_doc_number] => 12295948 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-13 [patent_title] => Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment [patent_app_type] => utility [patent_app_number] => 18/513888 [patent_app_country] => US [patent_app_date] => 2023-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7095 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18513888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19579840 [patent_doc_number] => 12145936 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-11-19 [patent_title] => 7-Imino-5-(1H-indol-3-yl)-1,3-substituted-7,8-dihdropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione as anti-inflammatory agents [patent_app_type] => utility [patent_app_number] => 18/510594 [patent_app_country] => US [patent_app_date] => 2023-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6092 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18510594 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20343071 [patent_doc_number] => 12466793 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-11 [patent_title] => Compounds for the treatment of SARS [patent_app_type] => utility [patent_app_number] => 18/504660 [patent_app_country] => US [patent_app_date] => 2023-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9160 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18504660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20127895 [patent_doc_number] => 12370195 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Oral compositions of MK2 pathway inhibitor for treatment of immune conditions [patent_app_type] => utility [patent_app_number] => 18/504778 [patent_app_country] => US [patent_app_date] => 2023-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 46 [patent_no_of_words] => 44742 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18504778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19297530 [patent_doc_number] => 20240226095 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2024-07-11 [patent_title] => METHOD FOR TREATING CANCER USING A BCL-2 INHIBITOR IN CONJUNCTION WITH AN ALPHA-EMITTING RADIOIMMUNOTHERAPEUTIC [patent_app_type] => utility [patent_app_number] => 18/500735 [patent_app_country] => US [patent_app_date] => 2023-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8095 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18500735 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19297530 [patent_doc_number] => 20240226095 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2024-07-11 [patent_title] => METHOD FOR TREATING CANCER USING A BCL-2 INHIBITOR IN CONJUNCTION WITH AN ALPHA-EMITTING RADIOIMMUNOTHERAPEUTIC [patent_app_type] => utility [patent_app_number] => 18/500735 [patent_app_country] => US [patent_app_date] => 2023-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8095 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18500735 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19998328 [patent_doc_number] => 20250136550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-01 [patent_title] => PROCESSES FOR PREPARING REVEFENACIN AND COMPOSITIONS COMPRISING THE SAME [patent_app_type] => utility [patent_app_number] => 18/496404 [patent_app_country] => US [patent_app_date] => 2023-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4821 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18496404 [rel_patent_id] =>[rel_patent_doc_number] =>)